CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy Systems of Care for ST-Segment–Elevation Myocardial Infarction: A Policy Statement From the American Heart Association ST-Segment Elevation Myocardial Infarction Patients in the Coronary Care Unit Is it Time to Break Old Habits? Another Nail in the Coffin for Intra-Aortic Balloon Counterpulsion in Acute Myocardial Infarction With Cardiogenic Shock Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials

Original ResearchVolume 13, Issue 10, May 2020

JOURNAL:JACC: Cardiovascular Interventions Article Link

Evaluation and Management of Nonculprit Lesions in STEMI

T Thim, NW van der Hoeven, C Musto et al. Keywords: CFR; FFR; iFR; nonculprit coronary lesions; STEMI

ABSTRACT

Nonculprit lesions are frequently observed in patients with ST-segment elevation myocardial infarction. Results from recent randomized clinical trials suggest that complete revascularization after ST-segment elevation myocardial infarction improves outcomes. In this state-of-the-art paper, the authors review these trials and consider how best to determine which nonculprit lesions require revascularization and when this should be performed.